SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now

REFERENCES

1. ↵
   1. Lewis EJ,
   2. Hunsicker LG,
   3. Bain RP,
   4. Rohde RD

   . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20):1456–1462. doi:10.1056/NEJM199311113292004

   OpenUrlCrossRefPubMed
2. ↵
   1. Lewis EJ,
   2. Hunsicker LG,
   3. Clarke WR,
   4. et al.
   5. Collaborative Study Group

   . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12):851–860. doi:10.1056/NEJMoa011303

   OpenUrlCrossRefPubMed
3. ↵
   1. Brenner BM,
   2. Cooper ME,
   3. de Zeeuw D,
   4. et al.
   5. RENAAL Study Investigators

   . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869. doi:10.1056/NEJMoa011161

   OpenUrlCrossRefPubMed
4. ↵
   1. Tsushima Y,
   2. Lansang MC,
   3. Makin V

   . The role of SGLT-2 inhibitors in managing type 2 diabetes. Cleve Clin J Med 2021; 88(1):47–58. doi:10.3949/ccjm.88a.20088

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. American Diabetes Association

   . 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 2020; 43(suppl 1):S98–S110. doi:10.2337/dc20-S009

   OpenUrlAbstract/FREE Full Text
6. ↵
   1. Garber AJ,
   2. Handelsman Y,
   3. Grunberger G,
   4. et al

   . Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 Executive Summary. Endocr Pract 2020; 26(1):107–139. doi:10.4158/CS-2019-0472

   OpenUrlCrossRef
7. ↵
   1. de Boer I,
   2. Luiza Caramori M,
   3. Chan J,
   4. et al

   . Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence-based advances in monitoring and treatment. Kidney Int 2020; 98(4):839–848. doi:10.1016/j.kint.2020.06.024

   OpenUrlCrossRefPubMed
8. ↵
   1. Wanner C,
   2. Inzucchi SE,
   3. Zinman B

   . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(18):1801–1802. doi:10.1056/NEJMc1611290

   OpenUrlCrossRefPubMed
9. 1. Packer M,
   2. Anker SD,
   3. Butler J,
   4. et al

   . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020 August 28; NEJMoa2022190. doi:10.1056/NEJMoa2022190

   OpenUrlCrossRefPubMed
10. 1. Neal B,
    2. Perkovic V,
    3. Mahaffey KW,
    4. et al

    . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7):644–657. doi:10.1056/NEJMoa1611925

    OpenUrlCrossRef
11. 1. Wiviott W,
    2. Raz I,
    3. Bonaca M,
    4. et al

    . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4):347–357. doi:10.1056/NEJMoa1812389

    OpenUrlCrossRefPubMed
12. ↵
    1. Perkovic V,
    2. Jardine MJ,
    3. Neal B,
    4. et al

    . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24):2295–2306. doi:10.1056/NEJMoa1811744

    OpenUrlCrossRefPubMed
13. ↵
    1. Heerspink HJL,
    2. Stefánsson BV,
    3. Correa-Rotter R

    . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15):1436–1446. doi:10.1056/NEJMoa2024816

    OpenUrlCrossRefPubMed
14. ↵ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection with Empagliflozin). Identifier NCT03594110
15. ↵
    1. Organ Procurement and Transplantation Network

    . AK OPTN/SRTR 2019 annual data report. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/
16. ↵
    1. Bakris GL,
    2. Agarwal R,
    3. Anker SD,
    4. Pitt B,
    5. et al.
    6. for the FIDELIO-DKD Investigators

    . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020 October 23. doi:10.1056/NEJMoa2025845

    OpenUrlCrossRefPubMed
17. ↵
    1. Heerspink PH,
    2. Parving H-H,
    3. Andress DL,
    4. et al.
    5. SONAR Committees and Investigators

    . Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393(10184):1937–1947. doi:10.1016/S0140-6736(19)30772-X

    OpenUrlCrossRefPubMed